In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Dicerna Pharma (DRNA), with a price target of $25.00. The company’s shares closed last Thursday at $20.00.
According to TipRanks.com, Nakae is a 4-star analyst with an average return of 12.0% and a 48.6% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Lineage Cell Therapeutics, and Emergent Biosolutions.
Dicerna Pharma has an analyst consensus of Strong Buy, with a price target consensus of $33.00, a 49.8% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $35.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $27.68 and a one-year low of $11.75. Currently, Dicerna Pharma has an average volume of 670.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson and John J. Rossi in 2007 and is headquartered in Watertown, MA.
Read More on DRNA:
